Wall Street analysts expect Regeneron (REGN Quick QuoteREGN - Free Report) to post quarterly earnings of $8.76 per share in its upcoming report, which indicates a year-over-year decline of 8.3%. Revenues are expected to be $3.25 billion, up 3.3% from the year-ago quarter.

The consensus EPS estimate for the quarter has been revised 6.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.

Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

Given this perspective, it's time to examine the average forecasts of specific Regeneron metrics that are routinely monitored and predicted by Wall Street analysts.

The combined assessment of analysts suggests that 'Revenues- Other Revenue' will likely reach $132.13 million. The estimate points to a change of +13% from the year-ago quarter.

Based on the collective assessment of analysts, 'Revenues- Net product sales' should arrive at $1.62 billion. The estimate indicates a year-over-year change of -8.2%.

Analysts predict that the 'Total Bayer collaboration revenue' will reach $374.73 million. The estimate suggests a change of +5.3% year over year.

The consensus estimate for 'Revenues- Collaboration' stands at $1.49 billion. The estimate points to a change of +17.9% from the year-ago quarter.

The consensus among analysts is that 'Revenues- Praluent (alirocumab)- US' will reach $57.71 million. The estimate points to a change of -17.6% from the year-ago quarter.

Analysts' assessment points toward 'Revenues- Eylea (Aflibercept)- US' reaching $1.19 billion. The estimate suggests a change of -15.2% year over year.

The collective assessment of analysts points to an estimated 'Revenues- Evkeeza- US' of $32.40 million. The estimate indicates a year-over-year change of +35%.

The average prediction of analysts places 'Revenues- Libtayo- ROW' at $127.95 million. The estimate indicates a change of +22.2% from the prior-year quarter.

Analysts expect 'Revenues- Libtayo- US' to come in at $214.99 million. The estimate indicates a year-over-year change of +35%.

It is projected by analysts that the 'Revenues- Dupixent (dupilumab)- ROW' will reach $1.08 billion. The estimate suggests a change of +25.7% year over year.

According to the collective judgment of analysts, 'Revenues- Kevzara (sarilumab)- ROW' should come in at $41.91 million. The estimate suggests a change of -5% year over year.

Analysts forecast 'Revenues- Kevzara (sarilumab)- US' to reach $52.50 million. The estimate indicates a year-over-year change of +5%.

View all Key Company Metrics for Regeneron here>>>

Over the past month, Regeneron shares have recorded returns of -8.2% versus the Zacks S&P 500 composite's -5.1% change. Based on its Zacks Rank #4 (Sell), REGN will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>